Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.

Michelotti, A; Venturini, M; Tibaldi, C; Bengala, C; Gallo, L; Carnino, F; Del Mastro, L; Lionetto, R; Montanaro, E; Rosso, R; Conte, P

Michelotti, A; Venturini, M; Tibaldi, C; Bengala, C; Gallo, L; Carnino, F; Del Mastro, L; Lionetto, R; Montanaro, E; Rosso, R; Conte, P.

Affiliation

Michelotti A; U. O. Oncologia Medica, Dipartimento di Oncologia Ospedale S. Chiara, Pisa, Italy.

Breast Cancer Res Treat ; 59(2): 133-9, 2000 Jan.

Article in En | MEDLINE | ID: mdl-10817348

Subject(s)

Antibiotics, Antineoplastic/therapeutic use; Breast Neoplasms/drug therapy; Epirubicin/therapeutic use; Adult; Aged; Antibiotics, Antineoplastic/adverse effects; Breast Neoplasms/pathology; Cardiovascular Agents/administration & dosage; Epirubicin/adverse effects; Female; Heart Failure/chemically induced; Humans; Injections, Intravenous; Middle Aged; Razoxane/administration & dosage; Treatment Outcome; Ventricular Dysfunction, Left/chemically induced

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Epirubicin / Antibiotics, Antineoplastic Type of study: Clinical_trials / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2000 Document type: Article Affiliation country: Italy Country of publication: Netherlands

Search on Google

Add to My VHL

XML

PubMed Links